Insulin lispro

Baron & Budd Represents Henrico County, Virginia in Lawsuit Against Pharmaceutical Manufacturers and Pharmacy Benefit Managers for Alleged Insulin Pricing Scheme

Retrieved on: 
Monday, November 20, 2023
Class Action Lawsuit, Professional Services, Legal, P.C, Government, Asbestos, Baron & Budd, P.C., Wildfire, Pharmacy, Insulin, Mesothelioma, Insulin lispro, PBM, Pharmaceutical industry

Today, the nationally recognized law firm Baron & Budd announced it is representing Henrico County, Virginia in a newly filed case against pharmaceutical manufacturers and pharmacy benefit managers (PBMs) alleging the defendants inflated the price of insulin and other diabetes medications.

Key Points: 
  • Today, the nationally recognized law firm Baron & Budd announced it is representing Henrico County, Virginia in a newly filed case against pharmaceutical manufacturers and pharmacy benefit managers (PBMs) alleging the defendants inflated the price of insulin and other diabetes medications.
  • Henrico County’s lawsuit alleges that the defendant pharmaceutical manufacturers colluded with pharmacy benefit managers to suppress competition and increase the prices of their insulins up to 1000%.
  • “Inflating the costs of life-saving medications, like insulin, puts an unnecessary financial burden on privately funded health plans,” said Baron & Budd Shareholder, Mark Pifko .
  • With more than 40 years of experience, Baron & Budd has the expertise and resources to handle complex litigation throughout the United States.

Baron & Budd Represents Arlington County, Virginia in Lawsuit Against Pharmaceutical Manufacturers and Pharmacy Benefit Managers for Alleged Insulin Pricing Scheme

Retrieved on: 
Friday, November 17, 2023
Class Action Lawsuit, Professional Services, Legal, P.C, Government, Asbestos, Baron & Budd, P.C., Wildfire, Pharmacy, Insulin, Mesothelioma, Insulin lispro, PBM, Pharmaceutical industry

The nationally recognized law firm Baron & Budd represents Arlington County, Virginia in a newly filed case against pharmaceutical manufacturers and pharmacy benefit managers (PBMs).

Key Points: 
  • The nationally recognized law firm Baron & Budd represents Arlington County, Virginia in a newly filed case against pharmaceutical manufacturers and pharmacy benefit managers (PBMs).
  • In the lawsuit, Arlington County alleges that the defendants inflated the price of insulin and other diabetes medications.
  • Arlington County’s lawsuit alleges that the defendant pharmaceutical manufacturers worked in tandem with pharmacy benefit managers to increase the prices of their insulins up to 1,000%, while also suppressing competition.
  • “Millions of individuals across the country need affordable access to life-saving medications like insulin,” said Baron & Budd Shareholder, Mark Pifko.

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

Retrieved on: 
Monday, December 18, 2023
Patient, Multimedia, Insulin lispro, Fine chemical, Mohs, Advance market commitments

DUBAI, UAE, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.

Key Points: 
  • Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia.
  • Biocon Biologics will now have a strong commercial footprint across ~120 countries with a direct presence in the U.S., Canada , Europe and 9 key Emerging Market countries of India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.
  • "I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries.
  • "This milestone presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets.

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

Retrieved on: 
Monday, December 18, 2023
Patient, Insulin lispro, Fine chemical, Mohs, Advance market commitments

DUBAI, UAE, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.

Key Points: 
  • All Viatris' biosimilars brands, including Ogivri® & Hertraz® (bTrastuzumab), Abevmy® (bBevacizumab), Fulphila® (bPegfilgrastim), Hulio® (bAdalimumab), Nepexto® (bEtanercept), Semglee® (bGlargine) and Kirsty® (bAspart) are now part of Biocon Biologics' commercial franchise in Advanced Markets and 80+ Emerging Markets .
  • Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia.
  • "I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries.
  • "This milestone presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets.

RxGo.com Offers Free Money Saving Coupons on Commonly Prescribed Diabetes Medications in Time for National Diabetes Month

Retrieved on: 
Wednesday, November 22, 2023
Metformin, Insulin, Ageing, Insulin glargine, Insulin lispro, Food, Patient, Pharmacy, Heart, Prescription, Health, Judgement, Cancer, Bangladesh Technical Education Board, Pharmaceutical industry, Diabetes

DENVER, Nov. 22, 2023 /PRNewswire-PRWeb/ -- In November, communities nationwide unite for National Diabetes Month to raise awareness about diabetes. This year emphasizes proactive measures to prevent health complications associated with diabetes. Diabetes, characterized by elevated blood glucose levels, impacts around 37 million Americans, posing risks to the eyes, kidneys, nerves, and heart, and increasing the likelihood of certain cancers.

Key Points: 
  • November marks National Diabetes Month, where communities nationwide emphasize preventing diabetes-related health issues, including taking medications on time.
  • Freestyle Libre 3 is actually not a medication but a small discrete glucose monitor for people with diabetes.
  • RxGo.com encourages people with a prescription for this drug to access a Metformin coupon today and immediately begin saving money.
  • It is prescribed for adults with type 1 or type 2 diabetes and for children aged at least 6 years with type 1 diabetes.

Meitheal Pharmaceuticals Joins Biosimilars Forum

Retrieved on: 
Tuesday, October 17, 2023
Medical Supplies, Medical Devices, Health, General Health, Pharmaceutical, Biotechnology, Diabetes, Insulin, Shea, Medication, Insulin glargine, Patient, Insulin lispro, Generic drug, Pharmaceutical industry

Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has joined the Biosimilars Forum, a growing coalition of companies that work together to make safe, effective and lower-cost biosimilars accessible to the patients that need them.

Key Points: 
  • Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has joined the Biosimilars Forum, a growing coalition of companies that work together to make safe, effective and lower-cost biosimilars accessible to the patients that need them.
  • “As a fully integrated biopharmaceutical company, Meitheal is thrilled to join the Biosimilars Forum,” said Tom Shea, CEO of Meitheal.
  • The Biosimilars Forum, a coalition of companies with the most significant biosimilars development portfolios in the U.S. and globally, is actively working to advance biosimilars in the U.S., with the ultimate goals of broadening access, enhancing availability and improving healthcare outcomes.
  • “The Biosimilars Forum is committed to fostering a competitive marketplace that enables safe, effective and lower-cost biosimilars to thrive.”
    Meitheal’s corporate purpose is to simplify access to life changing medicine, for good.

Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.

Retrieved on: 
Thursday, September 21, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Medical Supplies, Insulin glargine, Insulin, Partnership, Insulin lispro, Medication, Patient, Insulin aspart, NKF, FDA, Pharmaceutical industry, Communal work

THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.

Key Points: 
  • THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.
  • Upon approval, THDB, NKF and Meitheal will receive royalties on all product sales in the United States.
  • “This collaboration reinforces the strength of NKF’s partnership with Meitheal and demonstrates our commitment to innovation and continued investment in our portfolio companies,” said Eric Tang, President of NKF.
  • “We look forward to bringing these three products one step closer to patients through this strategic partnership.”

Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"

Retrieved on: 
Tuesday, June 20, 2023
Learning, Insulin, Diabetes, Pharmacy, Medicare, NYSE, LLY, American Diabetes Association, Diagnosis, Eli Lilly and Company, ADA, Insulin lispro, Disease, Pharmaceutical industry, Lilly

INDIANAPOLIS, June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association® (ADA) and Adam Duvall, American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all people living with diabetes.

Key Points: 
  • INDIANAPOLIS, June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association® (ADA) and Adam Duvall, American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all people living with diabetes.
  • Lilly will also give back to the diabetes community through contributions to local ADA summer camps.
  • And we promised we wouldn't stop there," said Mike Mason, president, Lilly Diabetes.
  • Lilly is also joined by Adam Duvall, who was diagnosed with type 1 diabetes in 2012 and is sharing his story of managing diabetes as a professional athlete.

Lilly ESG Report Highlights Progress Towards Sustainability Goals

Retrieved on: 
Monday, May 22, 2023
Insulin, Woman, UNICEF, Social Security Government Pension Offset, LLY, Patient, Diversity, Notifiable disease, Biophysical environment, DEI, Eli Lilly and Company, ESG, Social, Insulin lispro, Environment, NYSE, Pharmaceutical industry, Lilly

INDIANAPOLIS, May 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to maintaining a strong and resilient company.

Key Points: 
  • Improved access to Lilly insulins in the U.S.
    INDIANAPOLIS, May 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to maintaining a strong and resilient company.
  • Notable sustainability highlights in the report include:
    Reducing greenhouse gas emissions in the company's operations by more than 20% from 2020 to 2022 despite significant business growth over the same timeframe.
  • For five consecutive years, Lilly has been in the top five of the DiversityInc Top 50 Companies for Diversity list.
  • To learn more about Lilly's 2022 ESG goals and progress, visit https://esg.lilly.com/ .

California Selects Civica Rx as Its Insulin Manufacturing Partner

Retrieved on: 
Saturday, March 18, 2023
Public Policy, Government, Pharmaceutical, State, Local, Managed Care, Health, Diabetes, Healthcare Reform, Hospitals, Insulin, Inc., Partnership, Insulin lispro, Patient, Risk, Insulin aspart, Pharmaceutical industry, Civica, Insulin glargine

Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

Key Points: 
  • Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
  • “California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom.
  • Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices.
  • The next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.